Safety issues with transdermal opioid medications - Australian and ...

More documents

Recommendations

Info

• FDA ALERT 7/15/2005; “Fentanyl Transdermal System (marketed as Duragesic) Information” • Then Update 12/21/2007: This update highlights important information on appropriate prescribing, dose selection, and the safe use of the fentanyl transdermal system.
Did the Alert make a difference? • “Despite these efforts FDA has continued to receive reports of death and life- threatening adverse events .. when the fentanyl patch was: • used to treat pain in opioid-na naïve patients • opioid-tolerant patients have applied more patches than prescribed, • changed the patch too frequently, • and exposed the patch to a heat source. “
Page 1 and 2: Safety issues with transdermal opio
Page 3 and 4: An example • Patient arrived in E
Page 5 and 6: Cross section of a Norspan transder
Page 7 and 8: New South Wales IIMS data 1. - Medi
Page 9 and 10: Well, this doesn’t t appear to be
Page 11 and 12: And again - a common notification
Page 13 and 14: Perceived problems with patches Per
Page 15 and 16: And the culprits are? 100 95 Notifi
Page 17: 100 80 Percent 60 Buprenorphine Bup
Page 21 and 22: Warnings at Home
Page 23 and 24: MIMS Prescribing information also c
Page 25 and 26: What can you do as pain specialists
Page 27 and 28: All about communication - 2

Safety issues with transdermal opioid medications - Australian and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?